SCHEMBL16474686

SCHEMBL16474686

COc1ccc(-c2ccc(=O)n(-c3ccc(Cl)cc3)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
RAB9A P51151 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
GLA P06280 1/20 0.46
HPGD P15428 3/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RAD51 Q06609 1/20 0.43
NPBWR1 P48145 1/20 0.43
MEN1 O00255 1/20 0.42
TP53 P04637 1/20 0.42
ALOX12 P18054 1/20 0.42
KMT2A Q03164 1/20 0.42
LMNA P02545 1/20 0.42
PTGS1 P23219 2/20 0.42
PTGS2 P35354 2/20 0.42
USP2 O75604 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474688 0.92 MEN1 (0.47) MAPTRXFP1HPGDALDH1A1GAA
SCHEMBL10059808 0.86 MAPT (0.51) MAPTRAB9AHPGDALDH1A1GAA
SCHEMBL10059918 0.85 HRH3 (0.53) RAB9AGLAHPGDALDH1A1MEN1
SCHEMBL16474689 0.85 HRH3 (0.53) RAB9AGLAHPGDALDH1A1MEN1
SCHEMBL16474699 0.85 BRD4 (0.50) MAPTRAB9ARXFP1ALDH1A1RAD51
SCHEMBL10079104 0.84 KDM4E (0.53) MAPTRAB9AHPGDALDH1A1GAA
SCHEMBL16474690 0.82 KMT2A (0.43) MAPTRAB9ARXFP1HPGDALDH1A1
SCHEMBL10079858 0.82 KDM4E (0.49) RAB9AHPGDGAASMN1; SMN2LMNA
SCHEMBL17612717 0.81 HRH3 (0.45) MAPTRAB9ARXFP1PTGS2MAT2A
SCHEMBL10059887 0.81 SCN5A (0.44) MAPTPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903991-B1 ANTI-FIBROTIC PYRIDINONES INTERMUNE INC (US) 2020-09-16 EP disclosed
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
WO-2015153683-A1 ANTI-FIBROTIC PYRIDINONES INTERMUNE, INC. (US) 2015-10-08 WO disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 MAPT 4377/4885RAB9A 2353/4885RXFP1 516/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 MAPT 4377/4885RAB9A 2353/4885RXFP1 516/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 MAPT 4377/4885RAB9A 2353/4885RXFP1 516/4885
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 MAPT 4377/4885RAB9A 2353/4885RXFP1 516/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 MAPT 4377/4885RAB9A 2353/4885RXFP1 516/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 MAPT 4377/4885RAB9A 2353/4885RXFP1 516/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 MAPT 4377/4885RAB9A 2353/4885RXFP1 516/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 MAPT 4377/4885RAB9A 2353/4885RXFP1 516/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 MAPT 4377/4885RAB9A 2353/4885RXFP1 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.